化合物Sirpiglenastat T62560

Product Introduction
Bioactivity


英文名: Sirpiglenastat

描述: Sirpiglenastat (DRP-104) 是一种谷氨酰胺 (glutamine) 拮抗剂，是DON的前药，具有抗肿瘤活性，通过抑制谷氨酰胺代谢和刺激先天性和适应性免疫系统来发挥作用。

体外活性: Treatment with Sirpiglenastat (DRP-104) exhibits broad immune cell modulation effects, including an increase in T cells, NK cells, and macrophages. Sirpiglenastat also reduces the levels of pro-tumorigenic cytokines such as VEGF and KC (IL-8)[1].

体内活性: In CT26 bearing mice, treatment with Sirpiglenastat (DRP-104) at a dose of 0.5 mg/kg through subcutaneous injection once a day for 5 days results in a 90% inhibition of tumor growth by day 12, with a median survival of 36 days[1].Additionally, Sirpiglenastat treatment (0.5 mg/kg; s.c) significantly inhibits tumor growth in the H22 model[1].

存储条件: keep away from direct sunlight,keep away from moisturePowder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度: DMSO : 80 mg/mL(181.21 mM)


相关产品: GLS1 Inhibitor-7 | 6-Diazo-5-oxo-L-nor-Leucine | L-Albizziin | UPGL00004 | GLS1 Inhibitor-4 | Glutaminase C-IN-2 | BPTES | BJJF078 | ZED-1227 | Glutaminase-IN-3

相关库: Drug Repurposing Compound Library

化合物Sirpiglenastat T62560信息由TargetMol中国为您提供，如您想了解更多关于化合物Sirpiglenastat T62560报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途